Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Schneider RK, et al. Among authors: bejar r. Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18. Cancer Cell. 2014. PMID: 25242043 Free PMC article.
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg J, Zhang L, Gore S, Al Baghdadi T, Maciejewski J, Liu J, Padron E, Komrojki R, Saber W, Abel G, Kroft SH, Harrington A, Grimes T, Reed H, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. DeZern AE, et al. Among authors: bejar r. Blood Adv. 2023 Jul 25;7(14):3749-3759. doi: 10.1182/bloodadvances.2022008578. Blood Adv. 2023. PMID: 36947201 Free PMC article.
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
Gorak EJ, Otterstatter M, Al Baghdadi T, Gillis N, Foran JM, Liu JJ, Bejar R, Gore SD, Kroft SH, Harrington A, Saber W, Starczynowski D, Rollison DE, Zhang L, Moscinski L, Wilson S, Thompson J, Borchert C, Sherman S, Hebert D, Walker ME, Padron E, DeZern AE, Sekeres MA. Gorak EJ, et al. Among authors: bejar r. Blood Adv. 2023 Oct 24;7(20):6120-6129. doi: 10.1182/bloodadvances.2023010061. Blood Adv. 2023. PMID: 37552083 Free PMC article. Clinical Trial.
The genetic basis of myelodysplastic syndromes.
Bejar R, Ebert BL. Bejar R, et al. Hematol Oncol Clin North Am. 2010 Apr;24(2):295-315. doi: 10.1016/j.hoc.2010.02.001. Hematol Oncol Clin North Am. 2010. PMID: 20359627 Review.
Clinical effect of point mutations in myelodysplastic syndromes.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Bejar R, et al. N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJMoa1013343. N Engl J Med. 2011. PMID: 21714648 Free PMC article.
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.
Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Mike Makrigiorgos G. Murphy DM, et al. Among authors: bejar r. Leukemia. 2013 Oct;27(10):2077-81. doi: 10.1038/leu.2013.160. Epub 2013 May 27. Leukemia. 2013. PMID: 23708912 Free PMC article. No abstract available.
What lies beyond del(5q) in myelodysplastic syndrome?
Adema V, Bejar R. Adema V, et al. Among authors: bejar r. Haematologica. 2013 Dec;98(12):1819-21. doi: 10.3324/haematol.2013.094912. Haematologica. 2013. PMID: 24323981 Free PMC article. No abstract available.
153 results